Dr. Boursi is an expert in Clinical Oncology and Radiotherapy in Sheba Medical Center.
Dr. Boursi graduated cum laude from the Sackler School of Medicine at Tel Aviv University. He passed his specialization in Internal Medicine in Sourasky Medical Center, Tel Aviv, and sub-specialization in Gastrointestinal oncology and Epidemiology of Cancer at the University of Pennsylvania, USA.
Dr. Boursi is a member of the Department of Epidemiology and Preventive Medicine at Sackler School of Medicine, Tel Aviv University. He is also a research fellow at Perelman School of Medicine, the University of Pennsylvania, in the US. Dr. Boursi focuses on research in the field of the prevention and early detection of cancer diseases, using epidemiological and genetic data as well as innovative technologies.
Dr. Boursi developed models for the early detection of colorectal cancer and pancreatic cancer. Dr. Boursi has published numerous articles in leading scientific journals,
He has featured his research in major oncology conferences and cited in the popular media.
Dr. Boursi is a member of the Israeli Association of Clinical Oncology and Radiotherapy (ISCORT) and the American Society for Cancer Research.
Conditions and treatment
- Doctor at Gastrointestinal Cancer Department
Education and Training
- B.Med.Sc Summa cum laude, Sackler School of Medicine, Tel-Aviv University
- Doctor of Medicine (MD) Magna cum laude, Sackler School of Medicine, Tel-Aviv University
- Clinical and research fellowship in GI oncology and cancer epidemiology, Perelman School of Medicine, University of Pennsylvania
- Elective period in Medical Oncology in MD Anderson Cancer Center
- Elective period in Medical Oncology in Mayo Clinic
- Advanced study in basic research at the Weizmann Institute
- Internal Medicine
- Medical Oncology
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G.
A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer. Margalit O, Mamtani R, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.
Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. Margalit O, Mamtani R, Yang YX, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.
Request a consultation
Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.
We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.
Request a consultation and a Sheba Case Manager will contact you shortly: